Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLO Allogene Therapeutics	$1.04 -1.0%	$1.27	$0.86 ▼ $3.78	$227.48M	0.35	5.10 million shs	3.66 million shs
ARTV Artiva Biotherapeutics	$2.76 +4.5%	$2.19	$1.47 ▼ $17.31	$67.43M	N/A	186,397 shs	72,275 shs
ETON Eton Pharmaceuticals	$17.14 +12.3%	$14.87	$3.52 ▼ $21.48	$459.70M	1.13	432,930 shs	804,028 shs
TRDA Entrada Therapeutics	$5.19 -2.1%	$6.90	$4.98 ▼ $21.79	$196.98M	-0.12	217,327 shs	308,342 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLO Allogene Therapeutics	0.00%	-3.70%	-18.75%	-11.11%	-55.17%
ARTV Artiva Biotherapeutics	0.00%	-2.47%	+35.29%	+31.43%	-75.58%
ETON Eton Pharmaceuticals	0.00%	+21.30%	+18.29%	-1.21%	+360.75%
TRDA Entrada Therapeutics	0.00%	-10.52%	-20.76%	-41.16%	-62.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLO Allogene Therapeutics	2.9835 of 5 stars	4.4	2.0	1.1	2.5	0.6
ARTV Artiva Biotherapeutics	2.3474 of 5 stars	3.5	0.0	1.3	1.7	1.3
ETON Eton Pharmaceuticals	1.9904 of 5 stars	3.5	1.0	2.1	1.7	0.6
TRDA Entrada Therapeutics	2.0801 of 5 stars	3.6	1.0	1.2	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLO Allogene Therapeutics	2.75	Moderate Buy	$8.44	711.97% Upside
ARTV Artiva Biotherapeutics	3.00	Buy	$17.80	544.93% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	73.08% Upside
TRDA Entrada Therapeutics	3.25	Buy	$25.67	394.54% Upside

Current Analyst Ratings Breakdown

Latest ARTV, ETON, ALLO, and TRDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/4/2025	ALLO Allogene Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform
8/4/2025	ALLO Allogene Therapeutics	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
6/11/2025	ARTV Artiva Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Buy	$12.00
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/20/2025	TRDA Entrada Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $20.00
5/16/2025	ETON Eton Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$24.00 ➝ $26.00
5/15/2025	ALLO Allogene Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $4.00
5/15/2025	ARTV Artiva Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$23.00 ➝ $18.00
5/14/2025	ALLO Allogene Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$9.00 ➝ $7.00
5/14/2025	ALLO Allogene Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$14.00 ➝ $10.00
5/14/2025	ALLO Allogene Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$10.00 ➝ $10.00

(Data available from 8/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLO Allogene Therapeutics	$20K	11,373.96	N/A	N/A	$2.01 per share	0.52
ARTV Artiva Biotherapeutics	$250K	269.71	N/A	N/A	$7.68 per share	0.36
ETON Eton Pharmaceuticals	$39.01M	11.78	N/A	N/A	$0.94 per share	18.23
TRDA Entrada Therapeutics	$210.78M	0.94	$1.59 per share	3.27	$11.46 per share	0.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLO Allogene Therapeutics	-$257.59M	-$1.23	N/A	N/A	N/A	N/A	-52.98%	-41.28%	8/13/2025 (Estimated)
ARTV Artiva Biotherapeutics	-$65.37M	N/A	0.00	N/A	N/A	N/A	-42.60%	-37.76%	N/A
ETON Eton Pharmaceuticals	-$3.82M	-$0.16	N/A	34.28	N/A	-7.10%	-0.73%	-0.22%	N/A
TRDA Entrada Therapeutics	$65.63M	-$1.78	N/A	N/A	N/A	-92.30%	-17.81%	-14.55%	8/12/2025 (Estimated)

Latest ARTV, ETON, ALLO, and TRDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	ALLO Allogene Therapeutics	-$0.28	N/A	N/A	N/A	N/A	N/A
8/7/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.01	-$0.10	-$0.09	-$0.10	$16.71 million	$18.93 million
8/6/2025	Q2 2025	ARTV Artiva Biotherapeutics	-$0.84	-$0.87	-$0.03	-$0.87	N/A	N/A
8/6/2025	Q2 2025	TRDA Entrada Therapeutics	-$0.86	-$1.04	-$0.18	-$1.04	$8.17 million	$1.98 million
5/13/2025	Q1 2025	ALLO Allogene Therapeutics	-$0.28	-$0.28	N/A	-$0.28	$0.00 million	N/A
5/13/2025	Q1 2025	ETON Eton Pharmaceuticals	$0.09	$0.07	-$0.02	-$0.06	$14.33 million	$17.28 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLO Allogene Therapeutics	N/A	N/A	N/A	N/A	N/A
ARTV Artiva Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TRDA Entrada Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLO Allogene Therapeutics	N/A	9.71	9.71
ARTV Artiva Biotherapeutics	N/A	13.84	13.84
ETON Eton Pharmaceuticals	1.14	1.77	1.16
TRDA Entrada Therapeutics	N/A	18.64	18.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLO Allogene Therapeutics	83.63%
ARTV Artiva Biotherapeutics	N/A
ETON Eton Pharmaceuticals	27.86%
TRDA Entrada Therapeutics	86.39%

Insider Ownership

Company	Insider Ownership
ALLO Allogene Therapeutics	13.20%
ARTV Artiva Biotherapeutics	21.40%
ETON Eton Pharmaceuticals	14.89%
TRDA Entrada Therapeutics	7.59%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLO Allogene Therapeutics	310	218.73 million	189.86 million	Optionable
ARTV Artiva Biotherapeutics	81	24.43 million	19.20 million	N/A
ETON Eton Pharmaceuticals	20	26.82 million	22.83 million	Optionable
TRDA Entrada Therapeutics	110	38.04 million	35.15 million	Optionable

ARTV, ETON, ALLO, and TRDA Headlines

Recent News About These Companies

Entrada Therapeutics (NASDAQ:TRDA) Rating Lowered to Sell at Wall Street Zen

August 11 at 2:31 AM | americanbankingnews.com

HC Wainwright Issues Pessimistic Outlook for TRDA Earnings

August 11 at 2:04 AM | marketbeat.com

Roth Capital Issues Pessimistic Forecast for TRDA Earnings

August 11 at 2:03 AM | marketbeat.com

William Blair Issues Negative Forecast for TRDA Earnings

August 11 at 2:03 AM | marketbeat.com

Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen

August 10 at 2:49 AM | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

August 9 at 6:01 PM | finance.yahoo.com

Entrada Therapeutics (TRDA) to Release Quarterly Earnings on Tuesday

August 6, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates

August 6, 2025 | zacks.com

Entrada Therapeutics Reports Second Quarter 2025 Financial Results

August 6, 2025 | globenewswire.com

Entrada Therapeutics (TRDA) Soars 5.6%: Is Further Upside Left in the Stock?

July 31, 2025 | zacks.com

5am Ventures v sells Entrada Therapeutics (TRDA) stock for $202k

July 13, 2025 | investing.com

Entrada therapeutics (TRDA) director Parmar sells $202k in stock

July 13, 2025 | investing.com

Ventures V. L.P. 5Am Sells 6,935 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 12, 2025 | insidertrades.com

Insider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 6,935 Shares of Stock

July 11, 2025 | marketbeat.com

Ventures V. L.P. 5Am Sells 20,065 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) Stock

July 11, 2025 | marketbeat.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Director Sells $202,500.00 in Stock

July 11, 2025 | marketbeat.com

Entrada Therapeutics (TRDA) 10% owners sell $866k in stock

July 3, 2025 | investing.com

Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Ventures V. L.P. 5Am Sells 6,422 Shares

July 2, 2025 | insidertrades.com

Entrada Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

June 3, 2025 | globenewswire.com

Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 2, 2025 | globenewswire.com

Entrada Therapeutics Receives Authorization in the European Union to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in Patients ...

May 29, 2025 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why the American Eagle Stock Rally Isn't Just Speculation
By Gabriel Osorio-Mazilli | July 28, 2025
View Why the American Eagle Stock Rally Isn't Just Speculation
3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
This Drone Stock Is on Sale Despite Big Army Contract
By Jeffrey Neal Johnson | July 31, 2025
View This Drone Stock Is on Sale Despite Big Army Contract
3 Stocks Riding the AI Data Center Buildout Wave
By Chris Markoch | August 6, 2025
View 3 Stocks Riding the AI Data Center Buildout Wave
PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator
By Leo Miller | July 27, 2025
View PEGA Surges 14%: There's Still Time to Ride This GenAI Innovator

ARTV, ETON, ALLO, and TRDA Company Descriptions

Allogene Therapeutics NASDAQ:ALLO

$1.04 -0.01 (-0.95%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.07 +0.03 (+3.27%)

As of 08:06 AM Eastern

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.

Artiva Biotherapeutics NASDAQ:ARTV

$2.76 +0.12 (+4.55%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$2.78 +0.02 (+0.72%)

As of 08:05 AM Eastern

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Eton Pharmaceuticals NASDAQ:ETON

$17.14 +1.88 (+12.32%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$17.26 +0.12 (+0.70%)

As of 08:12 AM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Entrada Therapeutics NASDAQ:TRDA

$5.19 -0.11 (-2.08%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$5.18 -0.02 (-0.29%)

As of 05:26 AM Eastern

Entrada Therapeutics, Inc., a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1. The company also offers ENTR-601-45 and ENTR-601-50, which are in preclinical trail for the treatment of Duchenne muscular dystrophy; and ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time